TGF-beta LAP
A fragment of the latency-associated peptide (LAP) of TGF-β released by plasma kallikrein, enabling non-invasive monitoring of TGF-β activation and fibrogenic activity in chronic diseases.
Key features and values
- Quantifies LAP fragments generated by plasma kallikrein-mediated cleavage.
- Reflects activation of latent TGF-β complexes, indicating fibrogenic signaling.
- Provides a non-invasive measure of TGF-β activation dynamics.
- Supports monitoring of disease progression and response to therapies targeting TGF-β pathways.
- Applicable in research on fibrotic diseases and conditions characterized by aberrant TGF-β activation.
- Facilitates evaluation of interventions aimed at modulating TGF-β activation.
- Complements other biomarkers for a comprehensive assessment of fibrogenic activity.
Description
The TGF-β LAP biomarker assay measures specific fragments of the latency-associated peptide (LAP) of TGF-β released by plasma kallikrein, serving as an indicator of TGF-β activation and fibrogenic activity. This non-invasive assay provides insights into the activation dynamics of TGF-β in chronic diseases. By quantifying LAP fragments generated by plasma kallikrein-mediated cleavage, the TGF-β LAP assay aids in monitoring disease progression, evaluating treatment efficacy, and understanding the underlying mechanisms of fibrogenesis. It serves as a valuable tool in research settings for assessing the dynamics of TGF-β activation.
Nordic Bioscience’s assays and services are research use only products and services and do not qualify for medical or diagnostic purposes.
